0000899243-16-021416.txt : 20160602
0000899243-16-021416.hdr.sgml : 20160602
20160602061659
ACCESSION NUMBER: 0000899243-16-021416
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160601
FILED AS OF DATE: 20160602
DATE AS OF CHANGE: 20160602
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REATA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001358762
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113651945
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2801 GATEWAY DRIVE SUITE 150
CITY: IRVING
STATE: TX
ZIP: 75063
BUSINESS PHONE: 972-865-2206
MAIL ADDRESS:
STREET 1: 2801 GATEWAY DRIVE SUITE 150
CITY: IRVING
STATE: TX
ZIP: 75063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meyer Colin John
CENTRAL INDEX KEY: 0001662392
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37785
FILM NUMBER: 161691071
MAIL ADDRESS:
STREET 1: C/O REATA PHARMACEUTICALS, INC.
STREET 2: 2801 GATEWAY DR. SUITE 150
CITY: IRVING
STATE: TX
ZIP: 75063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-06-01
0
0001358762
REATA PHARMACEUTICALS INC
RETA
0001662392
Meyer Colin John
2801 GATEWAY DRIVE, SUITE 150
IRVING
TX
75063
0
1
0
0
See Remarks
Class A common stock
2016-06-01
4
C
0
10172
A
10172
D
Class A common stock
2016-06-01
4
P
0
10000
11.00
A
20172
D
Class B common stock
2016-06-01
4
C
0
10172
0.00
D
Class A common stock
10172
113985
D
The Class B common stock is convertible into Class A common stock on a one-for-one basis (a) at the holder's election at any time after the date that is six months following the date of the closing of the initial public offering of the company's Class A common stock, (b) at the holder's election prior to that time subject to certain conditions, or (c) at the option of the company's board of directors, in its sole discretion, at any time or multiple times from time to time on or before the closing of the initial public offering. The conversion right of the Class B common stock has no expiration date.
Chief Medical Officer and Vice President, Product Development
/s/ Michael D. Wortley, attorney-in-fact
2016-06-01